373110 — Xcell Therapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩41bn
- KR₩38bn
- KR₩2bn
Annual income statement for Xcell Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 1,966 | 1,020 | 1,124 | 1,934 |
| Cost of Revenue | ||||
| Gross Profit | -305 | -1,743 | -1,857 | -1,392 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 7,671 | 9,317 | 9,984 | 11,261 |
| Operating Profit | -5,705 | -8,297 | -8,860 | -9,327 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -9,038 | -8,342 | -9,281 | -9,543 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -9,038 | -8,342 | -9,281 | -9,543 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -9,038 | -8,342 | -9,281 | -9,543 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -9,038 | -8,342 | -9,281 | -9,543 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -835 | -770 | -845 | -941 |
| Dividends per Share |